Birnie Gemma L, Fry Darren R, Best Matthew P
From the Small Animal Medicine Department, Brisbane Veterinary Specialist Centre, Albany Creek, Queensland, Australia; and Australian Animal Cancer Foundation, Albany Creek, Queensland, Australia.
J Am Anim Hosp Assoc. 2018 Jul/Aug;54(4):188-194. doi: 10.5326/JAAHA-MS-6548. Epub 2018 May 14.
This prospective clinical trial was designed to evaluate the safety of hyperbaric oxygen therapy (HBOT) in a population of cats and dogs with a variety of naturally occurring diseases. Seventy-eight dogs and twelve cats with various naturally occurring disease conditions, who had the potential to benefit from HBOT, were enrolled in the study. These patients were treated with HBOT in a monoplace hyperbaric oxygen chamber at 2 air pressure absolute for a treatment length of either 45 min or 60 min. There were 230 hyperbaric oxygen treatments performed during the study period. No major adverse effects were observed. There were 76 minor adverse effects recorded, which were not considered to be of clinical significance. Hyperbaric oxygen therapy was well tolerated and there were no major adverse effects recorded during treatment.
这项前瞻性临床试验旨在评估高压氧疗法（HBOT）对患有各种自然发生疾病的猫和狗群体的安全性。78只狗和12只患有各种自然发生疾病的猫被纳入该研究，这些动物有从高压氧疗法中获益的潜力。这些患者在单舱高压氧舱中接受2个绝对大气压的高压氧治疗，治疗时长为45分钟或60分钟。研究期间共进行了230次高压氧治疗。未观察到重大不良反应。记录到76次轻微不良反应，但这些反应不被认为具有临床意义。高压氧疗法耐受性良好，治疗期间未记录到重大不良反应。
